Xbrane Biopharma: Raising SEK 170m in Directed Share Issue - Redeye

Yesterday evening Xbrane carried out a directed share issue of SEK 170m to strengthen the balance sheet ahead of the forthcoming Q1 2023 launch of Ximluci. Considering the relatively low discount, we interpret the directed share issue positively, emphasizing the current stressed market conditions in terms of financing. We update our DCF for the dilution and net proceeds, which renders an adjusted fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/858490/xbrane-biopharma-raising-sek-170m-in-directed-share-issue?utm_source=finwire&utm_medium=RSS